Reckitt Offloads Troubled Chinese Infant Nutrition Business
Executive Summary
Reckitt is to divest its Chinese infant formula business in a deal worth $2.2bn following a strategic review of the troubled unit.
You may also be interested in...
Perrigo Supports Hypoallergenic Infant Formula Savings Claims, Not Equivalence To Enfamil Brand
Perrigo can continue claiming its store brand hypoallergenic infant formula saves customers more than 20% compared to leading name brands while providing similar nutrition to leading brands. But meeting AAP standard doesn’t measure up as equivalent to brands, industry self-regulation group says.
Reckitt's CEO Unexpectedly Quits After Three Years At The Helm
Reckitt's CEO Laxman Narasimhan will leave the company at the end of September motivated by a desire to return to the US. Company director Nicandro Durante will take the reins on an interim basis while the UK-based health and hygiene giant seeks a long-term replacement.
Reckitt Restructure Seeks To Maximize Dietary Supplement Growth
Reckitt has identified “lots of growth spaces and lots of growth potential” for its vitamins, minerals and supplements business, which it will seek to capitalize on by moving the operation to its OTC-focused Health unit.